ANAVEX 3-71


Dual allosteric M1 muscarinic acetylcholine receptor agonist and sigma-1 receptor agonist

A spirocyclic thiadiazine-piperidine compound developed at the Israel Institute for Biological Research as a dual allosteric M1 muscarinic and sigma-1 receptor agonist, distinguished by sub-nanomolar allosteric potency at M1, disease-modifying preclinical efficacy in transgenic Alzheimer’s disease models, and active clinical development across schizophrenia, frontotemporal dementia, and Alzheimer’s disease indications.

Abstract

ANAVEX 3-71 (development code AF710B; CAS 1235733-73-9) is a synthetic spirocyclic thiadiazine-piperidine compound and a dual allosteric agonist at the M1 subtype of the muscarinic acetylcholine receptor and the sigma-1 receptor (SIGMAR1). The compound was invented by Abraham Fisher at the Israel Institute for Biological Research (IIBR) in Ness Ziona, Israel, as the fourth generation of a series of cholinergic agonists (AF102B, AF267B, AF292, AF710B) with progressively greater selectivity and allosteric character at the M1 muscarinic receptor. ANAVEX 3-71 emerged from high-throughput receptogram profiling as a compound with sub-nanomolar allosteric binding affinity at M1 muscarinic receptors (approximately 0.05 nM) and nanomolar affinity at the sigma-1 receptor (Ki approximately 1.3 nM), with no agonistic activity at M2 through M5 muscarinic subtypes, no significant binding at alpha-4-beta-2 or alpha-7 nicotinic receptors, and a clean off-target profile across 83 additional G-protein-coupled receptors, ion channels, and transporters screened at 10 micromolar. The preclinical pharmacology of ANAVEX 3-71 has been characterized principally in three studies using transgenic rodent models of Alzheimer’s disease. Orciani et al. (2023) demonstrated that early (preplaque, 7 months of age) treatment at the same dose for 7 months prevented cognitive impairment, reduced hippocampal plaque burden and cortical amyloid-beta peptides, attenuated microglial and astrocytic neuroinflammation, and rescued pro-BDNF to mature BDNF conversion, with effects persisting through a 4-week washout. No clinically relevant effects on QTc or other electrocardiographic parameters were observed across the full studied dose range. Food had no effect on the pharmacokinetics of ANAVEX 3-71 or its M8 metabolite. Clinical development is ongoing across multiple indications. A Phase 2 study in schizophrenia (NCT06245213; 71 subjects) reported dose-dependent improvements in electroencephalographic biomarkers and favorable safety and tolerability with no serious treatment-emergent adverse events. A modified-release oral tablet enabling once-daily dosing was successfully developed in a Phase 1b study completed in October 2025. ANAVEX 3-71 is not approved by any regulatory authority and is supplied as a research-grade preparation. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph